ctDNA Analysis Links Early Lorlatinib Progression to Genomic Complexity in ALK+ NSCLC

This study from the CROWN trial uses ctDNA data to identify that early progression on lorlatinib in ALK-positive non-small cell lung cancer (NSCLC) is associated with genomic complexity, TP53 mutations, and bypass pathways rather than new ALK resistance mutations. The findings provide insight into mechanisms behind early drug resistance in this patient group.

Originally published by gnews